DOI: https://doi.org/10.71112/2555vk32
1148 Revista Multidisciplinar Epistemología de las Ciencias | Vol. 2, Núm. 2, 2025, abril-junio
investigación. https://dialnet.unirioja.es/servlet/libro?codigo=775008&info=resumen&idio
ma=SPA
Hingorani, S. K., Shah, A. Y., & Mehta, C. D. (2023). Educational intervention to improve
knowledge, attitude, and practice of pharmacovigilance among resident doctors at a
tertiary care hospital. Perspectives in Clinical Research, 14(2), 75–
80. https://doi.org/10.4103/picr.picr_37_22
Hodkinson, A., Tyler, N., Ashcroft, D. M., Keers, R. N., Khan, K., Phipps, D., Abuzour, A.,
Bower, P., Avery, A., Campbell, S., & Panagioti, M. (2020). Preventable medication harm
across health care settings: A systematic review and meta-analysis. BMC Medicine,
18(1). https://doi.org/10.1186/s12916-020-01774-9
Hussain, R., Akram, T., Hassali, M. A., Muneswarao, J., ur Rehman, A., Hashmi, F., & Babar,
Z. U. D. (2022). Barriers and facilitators to pharmacovigilance activities in Pakistan: A
healthcare professionals-based survey. PLoS ONE, 17(7),
e0271587. https://doi.org/10.1371/journal.pone.0271587
Jeetu, G., & Anusha, G. (2010). Pharmacovigilance: A worldwide master key for drug safety
monitoring. Journal of Young Pharmacists, 2(3), 315–320. https://doi.org/10.4103/0975-
1483.66802
Laura, D., Martín, G., & García-Martín, D. L. (2023). Papel del servicio de seguimiento
farmacoterapéutico en la notificación de reacciones adversas y actualización de datos
de seguridad basados en la evidencia. Desarrollo de caso clínico. Pharmaceutical Care
España, 25(4), 38–45. https://doi.org/10.60103/phc.v25i4.814
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998). Incidence of adverse drug reactions in
hospitalized patients: A meta-analysis of prospective studies. JAMA, 279(15), 1200–
1205. https://doi.org/10.1001/jama.279.15.1200